AU2008355098B2 - Heterocyclic compounds - Google Patents

Heterocyclic compounds Download PDF

Info

Publication number
AU2008355098B2
AU2008355098B2 AU2008355098A AU2008355098A AU2008355098B2 AU 2008355098 B2 AU2008355098 B2 AU 2008355098B2 AU 2008355098 A AU2008355098 A AU 2008355098A AU 2008355098 A AU2008355098 A AU 2008355098A AU 2008355098 B2 AU2008355098 B2 AU 2008355098B2
Authority
AU
Australia
Prior art keywords
compound
solution
preparation
prepared
added
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2008355098A
Other languages
English (en)
Other versions
AU2008355098A1 (en
Inventor
Gholam Hossein Hakimelahi
Cheng-Kung Hu
Chang-Pin Huang
Ying-Huey Huang
Chi-Hsin Richard King
Chi-Feng Yen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Gpcr Therapeutics Inc
Original Assignee
Gpcr Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gpcr Therapeutics Inc filed Critical Gpcr Therapeutics Inc
Publication of AU2008355098A1 publication Critical patent/AU2008355098A1/en
Application granted granted Critical
Publication of AU2008355098B2 publication Critical patent/AU2008355098B2/en
Assigned to GPCR THERAPEUTICS, INC reassignment GPCR THERAPEUTICS, INC Request for Assignment Assignors: TAIGEN BIOTECHNOLOGY CO., LTD.
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/50—Three nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D251/00—Heterocyclic compounds containing 1,3,5-triazine rings
    • C07D251/02—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
    • C07D251/12—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D251/26—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hetero atoms directly attached to ring carbon atoms
    • C07D251/40—Nitrogen atoms
    • C07D251/54—Three nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Vascular Medicine (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Neurosurgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Dermatology (AREA)
  • Obesity (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
AU2008355098A 2008-04-21 2008-11-03 Heterocyclic compounds Active AU2008355098B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US4649608P 2008-04-21 2008-04-21
US61/046,496 2008-04-21
PCT/US2008/082202 WO2009131598A1 (en) 2008-04-21 2008-11-03 Heterocyclic compounds

Publications (2)

Publication Number Publication Date
AU2008355098A1 AU2008355098A1 (en) 2009-10-29
AU2008355098B2 true AU2008355098B2 (en) 2012-11-15

Family

ID=41201620

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2008355098A Active AU2008355098B2 (en) 2008-04-21 2008-11-03 Heterocyclic compounds

Country Status (20)

Country Link
US (1) US8372849B2 (enExample)
EP (1) EP2268635B1 (enExample)
JP (1) JP5661607B2 (enExample)
KR (1) KR101579999B1 (enExample)
CN (1) CN101565404B (enExample)
AU (1) AU2008355098B2 (enExample)
CA (1) CA2720229C (enExample)
CY (1) CY1116802T1 (enExample)
DK (1) DK2268635T3 (enExample)
EA (1) EA019289B1 (enExample)
ES (1) ES2545731T3 (enExample)
HR (1) HRP20150932T2 (enExample)
HU (1) HUE025179T2 (enExample)
NZ (1) NZ588989A (enExample)
PL (1) PL2268635T3 (enExample)
PT (1) PT2268635E (enExample)
SI (1) SI2268635T1 (enExample)
TW (1) TWI444188B (enExample)
WO (1) WO2009131598A1 (enExample)
ZA (1) ZA201008262B (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9023834B2 (en) * 2008-11-13 2015-05-05 Taigen Biotechnology Co., Ltd. Lyophilization formulation
CN103204816B (zh) * 2012-01-16 2016-04-27 中国人民解放军军事医学科学院毒物药物研究所 哌嗪基嘧啶类衍生物及其制备方法和用途
US9522917B2 (en) * 2012-04-11 2016-12-20 Acerta Pharma B.V. Bruton's tyrosine kinase inhibitors for hematopoietic mobilization
US9862703B2 (en) 2014-09-22 2018-01-09 National Health Research Institutes Heterocyclic compounds and use thereof
US9375406B2 (en) * 2014-09-30 2016-06-28 Taigen Biotechnology Co., Ltd. Substituted pyrimidines for mobilizing cells expressing a type 4 CXC chemokine receptor
TWI620748B (zh) 2016-02-05 2018-04-11 National Health Research Institutes 氨基噻唑化合物及其用途
RU2756055C2 (ru) * 2017-01-10 2021-09-24 Нэшнл Хелт Рисерч Инститьютс Гетероциклические соединения и их применение
CN109553604B (zh) * 2017-09-25 2021-08-27 盛世泰科生物医药技术(苏州)有限公司 4-氨基嘧啶衍生物作cxcr4抑制剂及其应用
CN108794414B (zh) * 2018-06-22 2021-01-01 浙江大学 芳酰胺基取代的均三嗪类化合物及制备和应用
CN116120195B (zh) * 2022-12-29 2025-02-25 长兴宜生药物科技有限公司 一种催化制备培哚普利中间体的方法
PL247377B1 (pl) * 2023-06-29 2025-06-23 Politechnika Krakowska Im Tadeusza Kosciuszki Nowa pochodna 1,3,5-triazyny i jej zastosowanie

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060281712A1 (en) * 2005-06-14 2006-12-14 Chi-Feng Yen Pyrimidine compounds

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6029A (en) * 1849-01-16 Method of directing the scoops in dredging machines
US3007A (en) * 1843-03-21 Improvement in salt-boilers
US5034560A (en) 1990-10-19 1991-07-23 The Standard Oil Company Synthesis of ethylamines
JP3340434B2 (ja) 1991-07-04 2002-11-05 ダコ アクティーゼルスカブ ジビニルスルホンに由来する成分を含んで成る水溶性ポリマーベース試薬及び抱合体
US5446090A (en) 1993-11-12 1995-08-29 Shearwater Polymers, Inc. Isolatable, water soluble, and hydrolytically stable active sulfones of poly(ethylene glycol) and related polymers for modification of surfaces and molecules
IL112795A (en) 1994-03-04 2001-01-28 Astrazeneca Ab Peptide derivatives as antithrombic agents their preparation and pharmaceutical compositions containing them
AU7692996A (en) 1995-12-01 1997-06-27 Ciba-Geigy Ag Receptor antagonists
TW440563B (en) 1996-05-23 2001-06-16 Hoffmann La Roche Aryl pyrimidine derivatives and a pharmaceutical composition thereof
WO1997046250A1 (en) 1996-06-04 1997-12-11 Synaptic Pharmaceutical Corporation Methods of modifying feeding behavior, compounds useful in such methods, and dna encoding a hypothalamic atypical neuropeptide y/peptide yy receptor (y5)
NO311614B1 (no) * 1996-10-01 2001-12-17 Janssen Pharmaceutica Nv Substituerte diamino-1,3,5-triazinderivater
TW520362B (en) * 1996-12-05 2003-02-11 Amgen Inc Substituted pyrimidine compounds and pharmaceutical composition comprising same
EP1054871A2 (en) 1998-04-01 2000-11-29 Du Pont Pharmaceuticals Company Pyrimidines and triazines as integrin antagonists
US6420354B1 (en) 1998-06-08 2002-07-16 Advanced Medicine, Inc. Sodium channel drugs and uses
IL141396A0 (en) 1998-08-20 2002-03-10 Agouron Pharma Non-peptide gnrh agents, methods and intermediates for their preparation
GB9905075D0 (en) 1999-03-06 1999-04-28 Zeneca Ltd Chemical compounds
US6274588B1 (en) 1999-05-31 2001-08-14 Hoffmann-La Roche Inc. 4-phenyl-pyrimidine derivatives
CA2396693A1 (en) * 1999-12-28 2001-07-05 Stephen T. Wrobleski Cytokine, especially tnf-alpha, inhibitors
CA2432799C (en) 2000-12-21 2008-08-19 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
US6897220B2 (en) 2001-09-14 2005-05-24 Methylgene, Inc. Inhibitors of histone deacetylase
MXPA04002397A (es) * 2001-09-14 2004-12-02 Methylgene Inc Inhibidores de histona deacetilasa.
WO2003026664A1 (en) 2001-09-26 2003-04-03 Bayer Corporation 2-phenylamino-4- (5-pyrazolylamino) -pyramidine derivatives as kinase inhibitors, in particular, src kinase inhibitors
WO2003028641A2 (en) 2001-10-01 2003-04-10 Taisho Pharmaceutical Co., Ltd. Mch receptor antagonists
ATE530530T1 (de) 2002-06-28 2011-11-15 Astellas Pharma Inc Diaminopyrimidincarbonsäureamidderivat
US7759336B2 (en) 2002-12-10 2010-07-20 Ono Pharmaceutical Co., Ltd. Nitrogen-containing heterocyclic compounds and medicinal use thereof
EP1590334B1 (en) 2003-01-30 2009-08-19 Boehringer Ingelheim Pharmaceuticals Inc. 2,4-diaminopyrimidine derivatives useful as inhibitors of pkc-theta
KR100806603B1 (ko) 2003-09-22 2008-02-29 에프. 호프만-라 로슈 아게 아미노알킬아미드 치환된 사이클로헥실 유도체
KR101258504B1 (ko) * 2004-03-26 2013-04-26 메틸진 인코포레이티드 히스톤 데아세틸라제의 억제제
EP1751115A4 (en) 2004-05-23 2010-10-20 Gerard M Housey THERAMUTEINMODULATOREN
JP2006124387A (ja) * 2004-09-30 2006-05-18 Taisho Pharmaceut Co Ltd 新規なキノリン、テトラヒドロキナゾリン、及びピリミジン誘導体と、これらを使用することに関連した治療方法
CA2620878A1 (en) 2005-08-29 2007-04-05 Gerard M. Housey Theramutein modulators
AU2006297089B2 (en) 2005-09-27 2012-05-03 Irm Llc Diarylamine-containing compounds and compositions, and their use as modulators of c-kit receptors
WO2007062213A2 (en) 2005-11-23 2007-05-31 Housey Pharmaceuticals Inc Compounds and methods of identifying, synthesizing, optimizing and profiling protein modulators
RU2008140382A (ru) 2006-03-16 2010-04-27 Новартис АГ (CH) Гетероциклические органические соединения, например, для лечения меланомы
WO2007129195A2 (en) 2006-05-04 2007-11-15 Pfizer Products Inc. 4-pyrimidine-5-amino-pyrazole compounds
EP2043651A2 (en) * 2006-07-05 2009-04-08 Exelixis, Inc. Methods of using igf1r and abl kinase modulators

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060281712A1 (en) * 2005-06-14 2006-12-14 Chi-Feng Yen Pyrimidine compounds
US20060293324A1 (en) * 2005-06-14 2006-12-28 Chi-Feng Yen Pyrimidine compounds

Also Published As

Publication number Publication date
SI2268635T1 (sl) 2015-10-30
WO2009131598A1 (en) 2009-10-29
AU2008355098A1 (en) 2009-10-29
EA019289B1 (ru) 2014-02-28
PL2268635T3 (pl) 2015-11-30
EP2268635A1 (en) 2011-01-05
EP2268635A4 (en) 2012-02-22
JP2011519360A (ja) 2011-07-07
ES2545731T3 (es) 2015-09-15
CA2720229A1 (en) 2009-10-29
HUE025179T2 (en) 2016-02-29
EA201071221A1 (ru) 2011-08-30
KR101579999B1 (ko) 2015-12-23
TW200944206A (en) 2009-11-01
HRP20150932T1 (xx) 2015-10-09
JP5661607B2 (ja) 2015-01-28
PT2268635E (pt) 2015-10-06
NZ588989A (en) 2012-03-30
CY1116802T1 (el) 2017-03-15
HK1138269A1 (en) 2010-08-20
HRP20150932T2 (hr) 2017-10-20
CN101565404B (zh) 2012-12-05
ZA201008262B (en) 2011-07-27
CA2720229C (en) 2015-02-17
DK2268635T3 (en) 2015-09-14
US8372849B2 (en) 2013-02-12
KR20110008085A (ko) 2011-01-25
TWI444188B (zh) 2014-07-11
US20090264339A1 (en) 2009-10-22
EP2268635B1 (en) 2015-06-10
CN101565404A (zh) 2009-10-28

Similar Documents

Publication Publication Date Title
AU2008355098B2 (en) Heterocyclic compounds
EP1890703B1 (en) Pyrimidine compounds as chemokine receptors inhibitors
JP5298187B2 (ja) タンパク質キナーゼ阻害剤としての化合物および組成物
US8193206B2 (en) Pyrimidine compounds
JP6359020B6 (ja) Ａｌｋキナーゼ阻害剤
JP5214799B2 (ja) キナーゼ阻害剤としての化合物および組成物
AU2004227943A1 (en) Novel compounds and compositions as protein kinase inhibitors
JP2011526291A (ja) キナーゼ阻害剤としてのピリミジン誘導体
ES2645470T3 (es) Moduladores del receptor cxcr7
US7501526B2 (en) Synthesis of polyamine compounds
HK1138269B (en) Heterocyclic compounds

Legal Events

Date Code Title Description
MK24 Application lapsed reg. 22.2e(2) - failure to pay response fee
NB Applications allowed - extensions of time section 223(2)

Free format text: THE TIME IN WHICH TO PAY THE EXAMINATION RESPONSE FEE HAS BEEN EXTENDED TO 13 OCT 2012 .

FGA Letters patent sealed or granted (standard patent)
PC Assignment registered

Owner name: GPCR THERAPEUTICS, INC

Free format text: FORMER OWNER(S): TAIGEN BIOTECHNOLOGY CO., LTD.